Covance 1Q Revenues: $634.3 million (+11%) 1Q Earnings: $48.2 million (+35%) Comments: Late-Stage Development revenues grew 17% to $373 million. Central laboratories and clinical development grew 20% and 18%, respectively. Early Development revenue was $207 million (-2%), with growth in clinical pharmacology, research products, and nutritional chemistry offsetting a decline in toxicology and discovery support services. Results include a $15.7 million gain on the sale of BioClinica, Inc. and r...